Chronic Kidney Disease Prognosis with Normal-Range Proteinuria

927 patients with stage G2-G5 chronic kidney disease were followed for a median of 35 months, tracking progression, cardiovascular events, and mortality. The study specifically analyzes 351 patients with normal-range proteinuria, a group often overlooked in health checkups. Data includes patient demographics, baseline kidney function, and longitudinal clinical outcomes.

Use Cases

• Analyze the hazard ratio for CKD progression between normal-range and abnormal-range proteinuria groups using multivariate Cox proportional hazard models.
• Model the risk of cardiovascular events and mortality across different CKD stages using Kaplan-Meier survival analysis on the 351-patient normal-range proteinuria cohort.
• Investigate the association between nephrosclerosis as a primary cause and clinical outcomes in patients with normal-range proteinuria.

Strengths

• Prospective cohort design with 927 patients followed for a median of 35 months, providing longitudinal outcome data.
• Detailed analysis of a specific 351-patient subgroup with normal-range proteinuria, a clinically understudied population.
• Clinical endpoints are clearly defined and quantified: 223 CKD progression events, 110 cardiovascular events, and 55 deaths in the full cohort.

Limitations

• Sample size for the key normal-range proteinuria subgroup is limited to 351 patients, with only 10 observed CKD progression events.
• Geographic and demographic bias is present, as the cohort is 70.2% male with a mean age of 67 years.
• Follow-up period is relatively short for a chronic disease study, with a median of 35-36 months.

Provenance

Source

Prospective cohort study (CKD-ROUTE) published in Dryad.

Collection Method

Clinical data from 1138 newly visiting stage G2-G5 CKD patients, with 927 included in the final analysis after a >6-month follow-up threshold.

Time Range

Study follow-up period with a median of 35 months.

Freshness

Data last updated in June 2020.